Harm Reduction Frameworks: Lessons for U.S. Opioid Policy

Background. For more than two decades, opioid-involved overdose mortality in the United States followed a steep upward trajectory — from prescription opioids in the 1990s ("first wave") to heroin (~2010s), illicit fentanyl (~2013–2020), and a "fourth wave" combining fentanyl with stimulants (cocaine, methamphetamine). After peaking above 110,000 deaths in a rolling twelve-month window in 2023, mortality reversed: the Centers for Disease Control and Prevention (National Center for Health Statistics [NCHS], 2026) estimated 81,313 deaths in 2024 and 69,973 in 2025, a 14% decline and the third consecutive year of decrease. Methods. We conducted an analytic review integrating three bodies of evidence: (a) federal statistics and official reports (CDC/NCHS, DEA, DOJ, GAO, CBO, CRS); (b) peer-reviewed research, including the HEALing Communities Study cluster-randomized trial ("New England Journal of Medicine", 2024), a supply-shock analysis published in "Science" (January 2026), and systematic reviews of drug checking and supervised consumption (2022–2025); and (c) U.S. policy instruments issued between April 2025 and May 2026, including Executive Order 14321 (July 24, 2025) and two SAMHSA Dear Colleague letters (July 2025; April 24, 2026). Results. The dominant driver of the 2023–2025 decline appears to be a disruption of the global illicit fentanyl supply — a "supply shock" associated with precursor-chemical restrictions — rather than expansion of treatment or harm reduction (Caulkins et al., 2026). At the same time, U.S. federal policy moved away from harm reduction: the April 24, 2026 SAMHSA letter removes fentanyl and xylazine test strips, sterile water, saline, ascorbic acid, and overdose support hotlines from funding eligibility, while retaining naloxone, nalmefene, education, and HIV/hepatitis prevention services. "Conclusions. " The mortality decline is neither a "victory" of enforcement-centered policy nor a validation of harm reduction alone; it is a supply-side event whose durability is uncertain. In a market that is stabilizing in some respects while becoming pharmacologically more hazardous (xylazine, medetomidine, nitazenes), harm reduction instruments serve as an early-warning and shock-absorbing layer. U.S. policy should integrate — rather than dislodge — that layer, while restoring systematic surveillance of the illicit drug supply.